Anavex Life Sciences Corp.

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-2024

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time

https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2024-third-quarter-financial-results-and-provides-business-updat

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 a.m. Eastern TimeNEW YORK – August 6, 2024Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's d...

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

https://www.anavex.com/post/anavex-life-sciences-to-announce-fiscal-2024-third-quarter-financial-results-on-tuesday-august-6-2

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ETNEW YORK – August 1, 2024Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disea...

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

- ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS)

- Therapeutic potential to address behavioral and cognitive deficits in individuals with neurodevelopmental disorders

- Plans advancing to initiate a clinical trial in individuals with FXS

https://www.anavex.com/post/anavex-life-sciences-announces-translational-biomarker-data-for-anavex-2-73-blarcamesine-in-fragil

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS)

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and noassociated neuroimaging adverse events

Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups

Benefits of blarcamesine on both amyloid-beta and brainvolume, two underlying pathological hallmarks of Alzheimer’s disease

EMA submission expected in Q4

https://www.anavex.com/post/results-from-anavex-life-sciences-landmark-phase-iib-iii-trial-of-blarcamesine-presented-at-alzheime

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and noassociated neuroimaging adverse events

Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups

Benefits of blarcamesine on both amyloid-beta and brainvolume, two underlying pathological hallmarks of Alzheimer’s disease

EMA submission expected in Q4

https://www.anavex.com/post/results-from-anavex-life-sciences-landmark-phase-iib-iii-trial-of-blarcamesine-presented-at-alzheime

www.anavex.com

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-h-c-wainwright-5th-annual-neuro-perspectives-virtual-confere

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference NEW YORK – June 20, 2024 Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’...

Anavex Life Sciences Announces Expansion of Leadership Team -

https://www.anavex.com/post/anavex-life-sciences-announces-expansion-of-leadership-team

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ



https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-h-c-wainwright-2nd-bioconnect-investor-conference-at-nasdaq

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2024-second-quarter-financial-results-and-provides-business

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

https://www.anavex.com/post/anavex-life-sciences-to-announce-fiscal-2024-second-quarter-financial-results-on-thursday-may-9th

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-noble-capital-markets-virtual-healthcare-equity-conference

From Autism to Alzheimer's: A recent study identifies brain energy metabolism dysfunction as a common driver of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, intellectual disability, autism spectrum disorders, schizophrenia, bipolar disorder, and depressive disorders.

SIGMAR1, which is activated by ANAVEX compounds, has been demonstrated to normalize brain energy metabolism at the mitochondrial level, upstream of pathways common to neurodegenerative, neurodevelopmental, and neuropsychiatric disorders.

The accumulation of 'junk proteins' has been identified as one cause of aging.

SIGMAR1, which is activated by ANAVEX compounds, has been demonstrated to reduce accumulation of junk proteins.

Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference



https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference at the 23rd Annual Needham Virtual Healthcare Conference - https://mailchi.mp/anavexcorp/httpswwwanavexcompostanavex-life-sciences-to-present-at-the-23rd-annual-needham-virtual-healthcare-conference

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia



https://www.anavex.com/post/anavex-life-sciences-initiates-placebo-controlled-u-s-phase-2-clinical-trial-of-anavex-3-71-in-schi

Anavex Life Sciences presents at the 44th Annual TD Cowen Health Care Conference

Link: https://wsw.com/webcast/cowen154/register.aspx?conf=cowen154&page=avxl&url=https://wsw.com/webcast/cowen154/avxl/2036306

DM us for the link as well.

Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference



https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-44th-annual-td-cowen-health-care-conference

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update



https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2024-first-quarter-financial-results-and-provides-business-updat

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024



https://www.anavex.com/post/anavex-life-sciences-to-announce-fiscal-2024-first-quarter-financial-results-on-wednesday-february

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans



https://www.anavex.com/post/anavex-life-sciences-reports-publication-of-anavex-3-71-in-clinical-journal-confirming-pharmacokinet

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

https://www.anavex.com/post/anavex-life-sciences-announces-phase-2-clinical-trial-anavex-3-71-schizophrenia

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

https://www.anavex.com/post/anavex-life-sciences-announces-grant-of-u-s-patent-covering-blarcamesine-anavex-2-73-for-treatmen

As we welcome the new year, we eagerly anticipate presenting at the 42nd Annual Healthcare Conference hosted by J.P. Morgan in San Francisco this week. Recognized as the most widely attended event with a diverse audience in the healthcare sector, this conference brings together companies, investors, and advisors for in-person interactions that spark discussions and set the stage for groundbreaking collaborations shaping the future of healthcare.

2024 holds promising developments and advancements in neuroscience therapeutics, and this conference serves as a pivotal force for transformation. We are enthusiastic about embarking on the journey into the new year and being part of !

Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference - https://mailchi.mp/anavexcorp/anavex-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference

Anavex Life Sciences Provides an Update on Rett Syndrome Program

https://mailchi.mp/anavexcorp/anavex-life-sciences-provides-an-update-on-rett-syndrome-program

Happy New Year!